# Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice

> **NCT00410306** · — · COMPLETED · sponsor: **Bayer** · enrollment: 1493 (actual)

## Conditions studied

- Male
- Hypogonadism

## Interventions

- **DRUG:** Testosterone Undecanoate (Nebido, BAY86-5037)

## Key facts

- **NCT ID:** NCT00410306
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 1493 (ACTUAL)
- **Last updated:** 2010-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00410306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00410306, "Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00410306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*